☆ 4.5 Article Proceedings Paper

Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios

JAMA NEUROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Clinical Neurology

Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease

Shorena Janelidze et al.

Summary: Plasma phospho-tau species, especially p-tau217, show promise as blood-based biomarkers for Alzheimer's disease. This study compared the performance of different assays for p-tau181, p-tau217, and p-tau231 in detecting abnormal A beta status and predicting progression to Alzheimer's dementia. The mass spectrometry-based p-tau217 (p-tau217(WashU)) demonstrated the best performance, while several immunoassays, including p-tau217(Lilly), p-tau217(Janss), p-tau181(ADx), and p-tau181(WashU), showed high accuracy in both outcomes.

BRAIN (2023)

Add to Collection

Article Medical Laboratory Technology

Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid

Johan Gobom et al.

Summary: The study evaluated the LUMIPULSE G assays for core cerebrospinal fluid biomarkers and established cutpoints for Alzheimer's disease diagnosis. Results showed strong correlation and reliable analytical performance of the LUMIPULSE G assays.

CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Performance of plasma phosphorylated tau 181 and 217 in the community

Michelle M. Mielke et al.

Summary: Plasma phosphorylated tau 181 (P-tau181) and 217 (P-tau217) can predict abnormal amyloid and tau pathology in community-based populations, but their predictive abilities vary across different brain regions, and are influenced by multiple comorbidities.

NATURE MEDICINE (2022)

Add to Collection

Article Clinical Neurology

Diagnostic and prognostic performance to detect Alzheimer's disease and clinical progression of a novel assay for plasma p-tau217

Colin Groot et al.

Summary: The study indicated good diagnostic and prognostic performance of the plasma p-tau217+(Janssen) assay, similar to the p-tau217(Lilly) assay.

ALZHEIMERS RESEARCH & THERAPY (2022)

Add to Collection

Article Multidisciplinary Sciences

Amyloid-associated increases in soluble tau relate to tau aggregation rates and cognitive decline in early Alzheimer's disease

Alexa Pichet Binette et al.

Summary: This study investigates the relationship between soluble phosphorylated tau (p-tau), tau aggregates, and cognitive decline in Alzheimer's disease (AD). The authors find that increased concentration of soluble p-tau is associated with the accumulation of insoluble tau aggregates and cognitive decline in the early stages of AD. The findings suggest that reducing soluble p-tau levels may be beneficial in early AD, before widespread insoluble tau aggregates.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Biomarkers for neurodegenerative diseases

Oskar Hansson

Summary: Biomarkers for neurodegenerative diseases play a crucial role in improving diagnostic workup and therapy monitoring, with emerging blood-based markers and discussions on their implementation in clinical practice and trials.

NATURE MEDICINE (2021)

Add to Collection

Article Clinical Neurology

Head-to-Head Comparison of 8 Plasma Amyloid-beta 42/40 Assays in Alzheimer Disease

Shorena Janelidze et al.

Summary: The study conducted in three different hospitals in Sweden from 2010 to 2014 found that certain mass spectrometry-based methods performed better for detecting brain A beta pathology compared to most immunoassays for plasma A beta 42/40 in patients with early Alzheimer's disease.

JAMA NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes

Michelle M. Mielke et al.

Summary: This study analyzed data from the Mayo Clinic Study on Aging conducted from 2015 to 2017, and found subtle differences in predicting cerebrovascular and Alzheimer-related pathology between different plasma p-tau species and measurement platforms. Some p-tau species were associated with white matter hyperintensity volume and white matter microstructural integrity.

JAMA NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Diagnostic Performance of RO948 F 18 Tau Positron Emission Tomography in the Differentiation of Alzheimer Disease From Other Neurodegenerative Disorders

Antoine Leuzy et al.

JAMA NEUROLOGY (2020)

Add to Collection

Article Medicine, General & Internal

Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders

Sebastian Palmqvist et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)

Add to Collection

Article Immunology

Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease

Nicolas R. Barthelemy et al.

JOURNAL OF EXPERIMENTAL MEDICINE (2020)

Add to Collection

Article Clinical Neurology

Untitled

ANNALS OF NEUROLOGY (2016)

Add to Collection

Editorial Material Urology & Nephrology

The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report

Andrew S. Levey et al.

KIDNEY INTERNATIONAL (2011)

Add to Collection

Article Medicine, Research & Experimental

Revised equations for estimating glomerular filtration rate based on the Lund-Malmo Study cohort

Jonas Bjork et al.

SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION (2011)

Add to Collection

Article Medicine, General & Internal

A New Equation to Estimate Glomerular Filtration Rate

Andrew S. Levey et al.

ANNALS OF INTERNAL MEDICINE (2009)

Add to Collection

© Peeref 2019-2024. All rights reserved.